[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fsgs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fsgs":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,61,99,124,151,180,209],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100591638","phase-2-atacicept-in-multiple-glomerular-diseases-100591638",false,"NCT06983028","Atacicept in Multiple Glomerular Diseases","A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)","Inclusion Criteria:\n\n* Weight of at least 40 kg\n* On a stable prescribed standard of care (SoC) treatment regimen according to local guidelines and the specific requirements for each disease\n* Systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤90 mmHg at Screening.\n\nDiagnosis of IgAN, IgAVN, pMN, MCD, FSGS, or primary nephrotic syndrome\n\nFor patients enrolling in IgAN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy proven IgAN, IgAVN, or recurrent IgAN in kidney transplant\n* UPCR ≥ 0.5 g\u002Fg or UPE ≥ 0.5 g\u002Fday on 24h urine\n* eGFR≥ 20 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pediatric IgAN Cohorts (eligibility varies by cohort):\n\n* Age ≥ 2 years and \\\u003C 18 years\n* Biopsy proven IgAN or IgAVN\n* On stable prescribed regimen of RAASi (or SoC) for at least 8 weeks\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* eGFR≥ 30 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pMN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy-proven pMN\n* Anti PLA2R antibodies ≥ 25 RU\u002FmL\n* UPCR ≥ 1.5 g\u002Fg or UPE ≥ 1.5 g\u002Fd on 24h urine\n* At low risk for spontaneous remission (based on severity or duration of disease)\n\nFor patients enrolling in Nephrotic Syndrome cohorts (MCD, FSGS, or pediatric idiopathic nephrotic syndrome):\n\n* Age ≥ 10 years\n* eGFR ≥30 mL\u002Fmin\u002F1.73m2\n* Adults with biopsy diagnosis of primary MCD or FSGS (adults) or children with challenging clinical course with steroids (frequenlty relapsing, steroid-dependent, or steroid-resistant)\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* Evidence of anti-nephrin antibodies\n\nKey Exclusion Criteria:\n\n* Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR) within 12 weeks prior to and at Screening)\n* Active viral or bacterial infections\n* Existing conditions or clinically significant laboratory abnormalities that may interfere with participation in this study\n* Administration of live and live-attenuated vaccinations within 30 days prior to enrollment\n* Immunosuppressant medications within 4 weeks prior to dosing with atacicept (except transplant maintenance immunosuppression).\n* Known hypersensitivity to atacicept or any component of the formulated atacicept\n* Additional criteria apply to each cohort\u002Fdisease.","ALL","2 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.",[26,27,28,29,30],"pMN","IgAN","Nephrotic Syndrome","MCD","FSGS",[32,33,34,35,36,37,28,38,39,40,41,42,43,44,45,46,47],"IGA Glomerulonephritis","IGA Nephropathy","Iga Nephropathy 1","Immunoglobulin A Nephropathy Nephritis","IGA Type Nephropathy, IGA","Primary Membranous Nephropathy","Immunoglobulin A (IgA)","Immunoglobulin A vasculitis with nephritis (IgAVN)","Anti-PLA2R associated membranous nephropathy (PLA2R-MN)","Idiopathic\u002Fprimary nephrotic syndrome (MCD\u002FFSGS)","Glomerulonephritis","Nephritis","Autoimmune Diseases","Immune System Diseases","Kidney Diseases","Glomerulonephritis, IGA","RECRUITING","2026-06-23",{"date":51,"type":52},"2026-06-26","ACTUAL",{"date":54,"type":52},"2025-07-07",{"date":56,"type":20},"2027-11",{"name":58,"class":59},"Vera Therapeutics, Inc.","INDUSTRY",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":75,"conditions":76,"keywords":84,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100406380","neptune-match-study-100406380","NCT04571658","NEPTUNE Match Study","Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)","NEPTUNE Match","Inclusion Criteria:\n\n1. Consented and eligible participants in the biopsied or non-biopsied cohorts of the NEPTUNE observational study\n2. Must be potentially eligible for the NEPTUNE Match partnering trials (e.g. if no trial is enrolling a participant under age 6, those under 6 are not eligible).\n\n   Note: NEPTUNE Match partnering trials and associated eligibility criteria are expected to be dynamic and change as trial protocols are developed, activated, and amended.\n3. Regular nephrology healthcare provided at a NEPTUNE study site.\n4. Willing and able to consent, and as appropriate assent, to participate in NEPTUNE Match\n\nExclusion Criteria:\n\nCurrently non-NEPTUNE observational study participants are not eligible to be matched to a clinical trial using these biomarker assessments.\n\nExclusion Criteria:\n\n1\\. Non-English or non-Spanish speaking","1 Year","80 Years",{"count":72,"type":20},375,[74],"NA","NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.",[77,78,79,80,81,30,29,82,83],"Nephrotic Syndrome in Children","Focal Segmental Glomerulosclerosis","Minimal Change Disease","Minimal Change Nephrotic Syndrome","Membranous Nephropathy","MCD - Minimal Change Disease","Alport Syndrome",[28,85,86,87],"NEPTUNE","Match","Clinical Trial Match","2026-06-08",{"date":90,"type":52},"2026-06-10",{"date":92,"type":52},"2022-05-02",{"date":94,"type":20},"2029-12-30",{"name":96,"class":97},"University of Michigan","OTHER",16,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":60},"100613471","phase-1-a-study-to-evaluate-the-safety-tolerability-and-pk-of-sk-09-100613471","NCT07267026","A Study to Evaluate the Safety, Tolerability and PK of SK-09","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of SK-09 in Healthy Adult Participants","Inclusion Criteria:\n\n1. Healthy male and female participants aged 18 to 55 years (inclusive) at the time of screening.\n2. Weight and BMI for female and male participants:\n\n   Body weight ≥ 50 kg; Body mass index (BMI) between 18.5 and 29.9 kg\u002Fm2 (inclusive)\n3. Participants must be in good general health.\n4. Capable of understanding and voluntarily providing written informed consent prior to any study-related procedures.\n5. Participants must have no plans for conception during the trial and for 3 months after the last dose, and must voluntarily use effective contraception with no plans for sperm or egg donation .\n\nExclusion Criteria:\n\n1. History or current presence of clinically significant Cardiovascular; Respiratory ; Gastrointestinal; Neurological ; Hematologic\u002Fimmunologic disorders.\n2. Chronic GI conditions requiring daily medication; or history of bariatric surgery.\n3. Live\u002Fattenuated vaccines within 4 weeks prior to dosing or planned during study.\n4. Systolic blood pressure \\\u003C 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure ≥80 mmHg.\n5. History of myocardial infarction, angina, coronary artery bypass grafting, angioplasty, stenting, congestive heart failure, uncontrolled hypotension, unexplained arrhythmia, ventricular tachycardia, atrioventricular block, QT prolongation syndrome, or symptoms\u002Ffamily history of QT prolongation syndrome, as assessed by the investigator to be unsuitable for participation.\n6. Positive results for hepatitis B surface antigen, syphilis-specific antibodies, hepatitis C antibodies, or HIV antibodies.\n7. Major surgery or trauma requiring hospitalization within 6 months.\n8. Hypersensitivity to any component of SK-09 or its excipients.\n9. Poor venous access or needle phobia impacting study procedures.\n10. History of alcohol abuse or binge drinking and\u002For any other illicit drug use or dependence within 6 months.\n11. Current smokers unwilling to abstain during study.\n12. Participants with ANY of the following abnormalities in clinical laboratory tests at screening and confirmed by a single repeat test, if deemed necessary:\n\n    * AST or ALT level ≥ 1.5×ULN;\n    * Total bilirubin level ≥ 1.5×ULN (except Gilbert's with direct bilirubin ≤ ULN)\n13. Blood loss or donation exceeding 400 mL within 3 months of dosing.\n14. Other investigational product within 30 days of dosing or 5 half-lives (whichever longer).\n15. Use of any medications, including over-the-counter drugs, herbal medicine, vitamins, and health supplements, within 2 weeks prior to the first dose or 5 half-lives (whichever longer).\n16. Positive pregnancy test or breastfeeding.\n17. Unprotected sexual activity within 2 weeks prior to the first dose.\n18. Any condition that, in the investigator's opinion, may pose a safety risk to the participant, interfere with the study, or prevent the participant from completing the study or complying with its requirements (due to administrative or other reasons).\n19. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.",true,"18 Years","55 Years",{"count":110,"type":20},72,[112],"PHASE1","This Phase 1 trial consists of two parts: Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study. Both parts adopt a randomized, double-blind, placebo-controlled design.",[30,29],"2026-06-04",{"date":117,"type":52},"2026-06-05",{"date":119,"type":52},"2025-12-08",{"date":121,"type":20},"2026-10-04",{"name":123,"class":59},"Consun Pharmaceutical Group",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":60},"100489246","recurrence-post-transplant-observational-study-in-focal-segmental-glomerulosclerosis-and-minimal-change-disease-100489246","NCT05650619","Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease","Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD)","RESOLVE","Inclusion Criteria:\n\n* Retrospective non-consented participant group had a transplant from the year 2000 and onward.\n* Diagnosis of FSGS or MCD in the native kidney (prior to transplant).\n\nExclusion Criteria:\n\n* Pathologic diagnosis other than FSGS or MCD\n* FSGS or MCD secondary to a known disorder (e.g. lupus nephritis, Immunoglobulin A (IgA) nephropathy, malignancy)",{"count":133,"type":20},300,"OBSERVATIONAL","The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry studies. Recent advances in the understanding of the mechanisms of FSGS in the native kidney has reinvigorated the scientific community to develop a collaborative community to advance research into the epidemiology, mechanisms, interventions, and outcomes.\n\nThe purpose of RESOLVE is to gather a group of people with FSGS and MCD that have had or will have a kidney transplant to create a bank of information and biospecimens so researchers can more effectively study these diseases.",[78,79,30,29],[138,139,140,141,142],"Kidney disease","Kidney transplant","Adult","Children","Recurrence","2026-04-23",{"date":145,"type":52},"2026-04-29",{"date":147,"type":52},"2022-12-08",{"date":149,"type":20},"2027-12",{"name":96,"class":97},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":70,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100453369","phase-3-a-study-of-the-efficacy-and-safety-of-dmx-200-in-patients-with-fsgs-who-are-receiving-an-arb-100453369","NCT05183646","A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB","A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)","ACTION3","DOUBLE BLIND PERIOD\n\nInclusion Criteria:\n\n1. Patients must be 12 to 80 years old\n2. A diagnosis of primary FSGS, genetic FSGS, or FSGS of undetermined cause. Confirmed by kidney biopsy within 7 years of screening\n3. Must be either receiving an ARB at the maximal tolerated dose or willing to transition\n4. If taking corticosteroids, the dosage must be stable for ≥4 weeks prior to Screening and during Stabilization\n5. If taking aldosterone inhibitors, mineralocorticoid receptor antagonists, direct renin inhibitors, sodium-glucose co-transporter-2 (SGLT2) inhibitors, or endothelin receptor antagonists (ERAs, including dual antagonists), the dose and regimen must be stable for ≥12 weeks prior to Screening and during Stabilization\n6. Urine PCR \\>1.5 g\u002Fg (\\>169.5 mg\u002Fmmol) or 24-hour total protein \\>1.5 g\u002Fday based on 24-hour urine collection during Screening.\n7. Estimated eGFR ≥25 and ≤120 mL\u002Fmin\u002F1.73 m2 at Screening for adults \\& eGFR ≥25mL\u002Fmin\u002F1.73 m2 for adolescent patients (\\\u003C18 years)\n8. Seated blood pressure ≤160\u002F100 mm Hg (mean of 3 values) (patients ≥18 years of age) or between the 5th and 95th percentile for age, sex, and height (patients \\\u003C18 years of age) at Screening\n9. Body weight ≥35 kg (all patients) AND a body mass index (BMI) ≤40 kg\u002Fm2 (patients ≥18 years of age) or between the 5th and 98th percentile for age and sex (patients \\\u003C18 years of age) at Screening.\n10. A female patient is eligible to participate if she is not pregnant or planning to become pregnant during the study, not breastfeeding, and at least one of the following conditions applies:\n\n    1. Is not of childbearing potential\n    2. If of childbearing potential and beginning at menarche, agrees to use a highly effective method of contraception consistently during the treatment period.\n11. A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception\n12. A patient or parent\u002Flegal guardian (as appropriate) who is capable of giving signed informed consent, and where required, the patient is capable of providing assent.\n\nExclusion Criteria:\n\n1. Has FSGS secondary to another condition.\n2. Patients with nephrotic syndrome (\\>3.5 g\u002Fday proteinuria and serum albumin \\\u003C30 g\u002FL) who have not previously been treated with standard of care FSGS-directed therapies (including steroids).\n3. History of type 1 diabetes mellitus, or uncontrolled type 2 diabetes mellitus (defined as glycated hemoglobin \\[HbA1c\\] \\>8% at Screening)\n4. History of lymphoma, leukemia, or any active malignancy within the past 2 years (except for basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ that have been resected and with no evidence of metastatic disease).\n5. Active clinically significant hepatobiliary disease.\n6. Documented history of heart failure (New York Heart Association Class III\u002FIV) or a major adverse cardiac event within 12 weeks prior to Screening.\n7. Has a physical, medical, or psychological condition, that in the opinion of the Investigator, may interfere with the evaluation the study.\n8. The patient has a history of alcohol or illicit drug use disorder within 1 year prior to Screening.\n9. Had a prior organ transplant or stem cell transplant, with the exception of corneal transplant.\n10. Positive screening assessment for viral hepatitis B surface antigen, or anti-hepatitis C virus (HCV) antibody AND positive HCV RNA, or human immunodeficiency virus 1 and 2.\n11. Serum potassium levels \\>5.5 mmol\u002FL at Screening.\n12. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\>2 × upper limit of normal (ULN) at Screening.\n13. Treatment with non-steroid immunosuppressant agents including biological drugs (e.g. rituximab), calcineurin inhibitors, cyclophosphamide, azathioprine, or mycophenolate mofetil within 12 weeks prior to Screening.\n14. History of serious side effects or allergic response to an angiotensin II antagonist or has a known sensitivity to any components in the IP.\n15. Unable to swallow oral medication.\n16. Prior participation in any Dimerix-sponsored DMX-200 clinical study.\n17. Participation in a clinical study with an investigational product (IP) within 28 days or 5 half-lives (whichever is longer) prior to Screening or plans to participate in another study during the course of this study.\n18. Are study site personnel directly affiliated with this study and their immediate families\n\nOLE PERIOD\n\nInclusion Criteria:\n\n1. A patient or parent\u002Flegal guardian (as appropriate) who is capable of giving signed informed consent, and where required, the patient is capable of providing assent.\n2. Patients who have completed participation in the double-blind period, including the Week 104 visit, and who may derive benefit from (continued) treatment with DMX-200, and\u002For continued follow-up\n3. The patient received blinded Investigational Product throughout the duration of the double-blind period up to the Week 104 visit\n4. The patient continues to meet the contraceptive requirements\n\nExclusion Criteria:\n\n1. The patient has met the criteria for permanent IP discontinuation or study discontinuation\n2. Any safety concerns identified during the double-blind period which, in the Investigator's opinion, may interfere with the patient's continued participation during the OLE period.","12 Years",{"count":161,"type":20},286,[163],"PHASE3","DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an ARB. Given the rarity of the disease and the similarities between adults and pediatric patients with FSGS, Dimerix will also investigate the efficacy and safety of DMX 200 in adolescents aged 12 to 17 years. The double-blind period will be followed by an open-label extension (OLE) which aims to assess the long-term efficacy and safety of DMX 200 for up to 2 additional years.",[30],[167,168,169],"fsgs","focal segmental glomerulosclerosis","kidney disease","2026-02-02",{"date":172,"type":52},"2026-02-03",{"date":174,"type":52},"2022-05-30",{"date":176,"type":20},"2029-12",{"name":178,"class":59},"Dimerix Bioscience Pty Ltd",220,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":190,"conditions":191,"keywords":199,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":60},"100478094","interview-study-of-adult-and-child-patients-and-parents-of-children-with-swelling-due-to-nephrotic-syndrome-100478094","NCT05505500","Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.","Preparing a Clinical Outcomes Assessment Set for Nephrotic Syndrome","Prepare-NS","Criteria for the Observer Reported Outcomes (ObsRO) cohort of the study:\n\nInclusion Criteria:\n\n1. Parents\u002Fguardians must be able to read and understand English;\n2. Parents\u002Fguardians must be caring for a child (ages 2-11.999) with a medically documented diagnosis of idiopathic (primary) Nephrotic Syndrome (NS) or primary or monogenic NS associated kidney disease. Populations with Primary NS Conditions: Focal segmental glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin M (IgM) Nephropathy, Membranous Nephropathy (MN), and childhood - onset nephrotic syndrome not biopsied;\n3. The child must have a current NS-associated edema\n4. The child must have native kidney function\n5. Parents\u002Fguardians must provide informed consent.\n\nExclusion Criteria:\n\n1\\. Index case with dialysis dependence throughout the 3-month pre-enrollment period\n\nCriteria for the Patient Reported Outcomes (PRO) cohort of the study:\n\nInclusion Criteria:\n\n1. ≥8 years of age\n2. Able to read and understand English\n3. Primary (idiopathic) kidney disease that causes NS or monogenic NS associated kidney disease.\n\n   i. Populations with Primary Nephrotic Syndrome (NS) Conditions include: FSGS, MCD, IgM nephropathy, MN, and childhood - onset nephrotic syndrome not biopsied\n4. Current NS-associated edema\n5. Kidney function with most recent estimated Glomerular Filtration Rate (eGFR) \\> 25 ml\u002Fmin\u002F1.73m2\n6. Informed Consent: For patients ≥8 to \\\u003C18 years of age: a parent or legal guardian provide informed consent and the patient must provide assent. Patients ≥18 years of age must provide informed consent.\n\nExclusion Criteria:\n\n1. Native kidney disease participant with dialysis dependence during the 3-month pre-enrollment period\n2. Co-existing significant chronic or severe acute health condition that has the potential to influence how the participant feels or functions as related to fluid overload in NS",{"count":189,"type":20},150,"Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome. Interviews with patients (child and adult) and parents of young children will be conducted. The information collected from the interviews will be used to develop a survey to use when testing new medications for Nephrotic Syndrome.\n\nPlease consider participating in a 1-hour long interview with the Prepare-NS research study to discuss children and adults experiences with swelling.",[192,193,194,81,79,80,195,28,196,197,77,198,30],"Fluid Overload","Glomerulosclerosis, Focal Segmental","Edema","IgM Nephropathy","Glomerular Disease","Nephrotic Syndrome, Minimal Change","Nephrotic Syndrome With Edema (Diagnosis)",[28,200,140,192,194,30,79,81,195],"Child","2025-12-15",{"date":203,"type":52},"2025-12-22",{"date":205,"type":52},"2022-04-18",{"date":207,"type":20},"2026-04-30",{"name":96,"class":97},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":21,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":60},"100478287","phase-1-early-trial-of-allogeneic-hematopoietic-stem-cell-transplantation-for-patients-who-will-receive-a-kidney-transplant-from-the-same-donor-100478287","NCT05508009","Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor","Phase 1b\u002F2a Trial of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From an HLA-partially Matched Related or Unrelated Donor After TCRαβ+ T-cell\u002FCD19+ B-cell Depletion for Patients Who Will Receive a Kidney Transplant (KT) From the Same HSCT\u002FKT Donor","Inclusion Criteria:\n\n* Anticipated need for kidney transplant due to:\n\n  a. Underlying genetic\u002Fimmunologic disease the following conditions i. SIOD ii. FSGS iii. Cystinosis iv. SLE v. Membranoproliferative glomerulonephritis vi. Renal vasculitis characterized by positivity of the presence of ANCA vii. Other genetic diseases leading to kidney disease requiring KT Or b. Patients who have rejected a previous KT regardless of the underlying disease\n* Chronic kidney disease (CKD) stage 3 or greater\n* Steroids \\\u003C 0.5 mg\u002FKg\u002Fday\n* The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DQB1 and HLA-DRB1\n* Lansky\u002FKarnofsky score \\> 50; the Karnofsky Scale will be used in subjects ≥ 16 years of age, and the Lansky Scale will be used for those \\\u003C 16 years of age.\n* Able to give informed consent or have an LAR available to provide consent\n* Male and female subjects of childbearing potential must agree to use an effective means of birth control to avoid pregnancy throughout the transplant procedure, while on immunosuppression, and if the subject experiences any cGvHD\n\nExclusion Criteria:\n\n* Pregnant or lactating females.\n* Greater than Grade II aGvHD or severe, unmanaged extensive cGvHD due to a previous allograft at the time of inclusion\n* Dysfunction of liver (ALT\u002FAST \\> 10 times upper normal value, or direct bilirubin \\> 3 times upper normal value), unmanageable dysfunction of renal function while undergoing dialysis\n* Severe cardiovascular disease at the time of evaluation unresponsive to nutritional and dialytic support (left ventricular ejection fraction \\\u003C 40%), or clinical or echocardiographic evidence of severe diastolic dysfunction\n* Current active infectious disease. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. Patients with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load.\n* Serious concurrent uncontrolled medical disorders except for primary disease leading to chronic kidney disease\n* Lack of patient\u002Fparent\u002Fguardian informed consent\n* Any severe concurrent disease which, in the judgement of the investigator would place the patient at increased risk during participation in the study","30 Years",{"count":218,"type":20},12,[112,23],"This is a single center, non-randomized, non-controlled open-label phase 1b\u002F2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT immunosuppression, to abrogate the need for lifelong immunosuppression, the risk of chronic rejection and, ultimately, the need for repeated transplantation.",[222,223,30,224,225],"SIOD","Cystinosis","SLE Nephritis","CKD Stage 4","2023-07-13",{"date":228,"type":52},"2023-07-17",{"date":230,"type":52},"2023-01-10",{"date":232,"type":20},"2034-10",{"name":234,"class":97},"Alice Bertaina"]